公开(公告)号：EP1140960A1

公开(公告)日：2001-10-10

申请号：EP00903234.3

申请日：2000-01-11

申请人： Cydex Inc.

发明人： STELLA, Valentino, J. ,  RAJEWSKI, Roger, A. ,  RAO, Venkatramana, M. ,  McGINITY, James, W. ,  MOSHER, Gerold, L.

IPC分类号： C07H13/12 ,  C08B37/16

CPC分类号： B82Y5/00 ,  A61K9/205 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/2826 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/4808 ,  A61K47/40 ,  A61K47/6951 ,  Y10S514/964 ,  Y10S514/965

摘要： Sulfoalkyl ether cyclodextrin (SAE-CD) based controlled release pharmaceutical formulations are provided by the present invention. The present solid pharmaceutical formulations consist of a core comprising a physical mixture of one or more SAE-CD derivatives, an optional release rate modifier, a therapeutic agent, a major portion of which is not complexed to the SAE-CD, and an optional release rate modifying coating surrounding the core. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative is used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents. Multi-layered, osmotic pump, coated, and uncoated tablet, minitablet, pellet, micropellet, particle, powder, and granule dosage forms are disclosed herein.

公开(公告)号：EP1140960B1

公开(公告)日：2007-09-26

申请号：EP00903234.3

申请日：2000-01-11

申请人： CyDex, Inc.

发明人： STELLA, Valentino, J. ,  RAJEWSKI, Roger, A. ,  RAO, Venkatramana, M. ,  McGINITY, James, W. ,  MOSHER, Gerold, L.

IPC分类号： A61K9/22 ,  A61K9/24 ,  A61K9/32 ,  A61K9/52 ,  A61K47/40 ,  C08B37/16

CPC分类号： B82Y5/00 ,  A61K9/205 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/2826 ,  A61K9/2846 ,  A61K9/2853 ,  A61K9/2866 ,  A61K9/4808 ,  A61K47/40 ,  A61K47/6951 ,  Y10S514/964 ,  Y10S514/965

摘要： Sulfoalkyl ether cyclodextrin (SAE-CD) based controlled release pharmaceutical formulations are provided by the present invention. The present solid pharmaceutical formulations consist of a core comprising a physical mixture of one or more SAE-CD derivatives, an optional release rate modifier, a therapeutic agent, a major portion of which is not complexed to the SAE-CD, and an optional release rate modifying coating surrounding the core. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative is used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents. Multi-layered, osmotic pump, coated, and uncoated tablet, minitablet, pellet, micropellet, particle, powder, and granule dosage forms are disclosed herein.